JPRN-UMIN000018758
Completed
未知
The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer. - The additional study of a phase II study of Neoadjuvant Eribulin in TNBC patients
Conditionsbreast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- breast cancer
- Sponsor
- ational Cancer Center Hospital
- Enrollment
- 43
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patient considered irrelevant by attending physician for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM)Type II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003053-37-BGBayer AG600
Active, not recruiting
Phase 1
A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM)Type II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003053-37-ESBayer AG600
Not yet recruiting
Not Applicable
Exploratory study of biomarker for complications as thrombosis after portal vein embolizatioPatient underwent portal vein embolizationJPRN-UMIN000014075Yokohama City University Graduate School of Medicine60
Completed
Not Applicable
Study on biomarkers for the effect and safety of the treatment with Atezolizumab + Bevacizumab for liver cancerunresectable advanced hepatocellular carcinomaJPRN-UMIN000047758agoya University Graduate School of Medicine99
Not yet recruiting
Not Applicable
Biomarker study for postoperative AKI of Emergency surgeryAcute abdomenJPRN-UMIN000037653St marianna University School of Medicine150